Antonia Kwan

2.9k total citations · 1 hit paper
41 papers, 1.5k citations indexed

About

Antonia Kwan is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Antonia Kwan has authored 41 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 19 papers in Immunology and 14 papers in Pathology and Forensic Medicine. Recurrent topics in Antonia Kwan's work include CAR-T cell therapy research (18 papers), Lymphoma Diagnosis and Treatment (14 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Antonia Kwan is often cited by papers focused on CAR-T cell therapy research (18 papers), Lymphoma Diagnosis and Treatment (14 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Antonia Kwan collaborates with scholars based in United States, Canada and United Kingdom. Antonia Kwan's co-authors include Jennifer M. Puck, Michael C. Wei, Lihua E. Budde, Nancy L. Bartlett, Sarit Assouline, Shen Yin, Laurie H. Sehn, Stephen J. Schuster, Chan Y. Cheah and Matthew Ku and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Antonia Kwan

39 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

2022 244 citations Lihua E. Budde, Laurie H. Sehn et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Antonia Kwan

Since Specialization

Citations

This map shows the geographic impact of Antonia Kwan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonia Kwan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonia Kwan more than expected).

Fields of papers citing papers by Antonia Kwan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonia Kwan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonia Kwan. The network helps show where Antonia Kwan may publish in the future.

Co-authorship network of co-authors of Antonia Kwan

This figure shows the co-authorship network connecting the top 25 collaborators of Antonia Kwan. A scholar is included among the top collaborators of Antonia Kwan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonia Kwan. Antonia Kwan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tocilizumab Dosing for Management of T Cell‐Engaging Bispecific Antibody‐Related CRS in Patients With R/R B‐Cell NHL 2025 ·Clinical Pharmacology & Therapeutics ·Candice Jamois, David C. Turner, Leonid Gibiansky, (unknown), (unknown), Leonardo Pereira, Linda Lundberg, Elena Guerini, David Carlile, James Relf, Michael C. Wei, Antonia Kwan, Nicolas Frey, Susan Grange	1
2	Subcutaneous Mosunetuzumab Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome, and Non-Inferior Exposure Compared with Intravenous Administration in Patients with Relapsed/Refractory Follicular Lymphoma: Primary Analysis of a Pivotal Phase II 2024 ·Blood ·Nancy L. Bartlett, Laurie H. Sehn, Sarit Assouline, Pratyush Giri, John Kuruvilla, Stephen J. Schuster, Sung Soo Yoon, Keith Fay, Georg Heß, Martin Dreyling, Norma C. Gutiérrez, (unknown), Antonia Kwan, Elicia Penuel, Samuel Tracy, (unknown), (unknown), Volker Wiebking, Michael C. Wei, Lihua E. Budde	4
3	Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study 2024 ·Journal of Clinical Oncology ·Lihua E. Budde, Sarit Assouline, Laurie H. Sehn, Stephen J. Schuster, Sung‐Soo Yoon, Dok Hyun Yoon, Matthew J. Matasar, Francesc Bosch, Won Seog Kim, Loretta J. Nastoupil, Ian W. Flinn, Mazyar Shadman, Catherine Diefenbach, Chan Y. Cheah, (unknown), Huang Huang, Antonia Kwan, Michael C. Wei, Shen Yin, Nancy L. Bartlett	34
4	Mosunetuzumab Monotherapy Demonstrates Encouraging Activity and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed or Refractory Mantle Cell Lymphoma 2024 ·Blood ·Lihua E. Budde, Matthew J. Matasar, Laurie H. Sehn, Sarit Assouline, John Kuruvilla, Ian W. Flinn, (unknown), Francesc Bosch, Daniel Greenwald, Norma C. Gutiérrez, Dimitrios Tzachanis, Paula Marlton, Delaney McGuirt, Shen Yin, Michael C. Wei, Antonia Kwan, Samuel Tracy, Elicia Penuel, Nancy L. Bartlett	4
5	IBCL-335 Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After ≥2 Prior Therapies: 3-Year Follow-Up From a Pivotal Phase II Study 2024 ·Clinical Lymphoma Myeloma & Leukemia ·Stephen J. Schuster, Laurie H. Sehn, Nancy L. Bartlett, Matthew J. Matasar, Sarit Assouline, Pratyush Giri, John Kuruvilla, Mazyar Shadman, Chan Y. Cheah, (unknown), Keith Fay, Loretta J. Nastoupil, Michael C. Wei, (unknown), Iris To, Jiangeng Huang, Antonia Kwan, Elicia Penuel, Lihua E. Budde	0
6	A Novel Step‐Up Dosage Regimen for Enhancing the Benefit‐to‐Risk Ratio of Mosunetuzumab in Relapsed or Refractory Follicular Lymphoma 2024 ·Clinical Pharmacology & Therapeutics ·Chi‐Chung Li, Brendan C. Bender, Justin Wilkins, (unknown), David C. Turner, Bei Wang, Rong Deng, Shweta Vadhavkar, Zao Li, Antonia Kwan, Huang Huang, Kun Peng, Elicia Penuel, Ling‐Yuh Huw, Pascal Chanu, (unknown), (unknown), (unknown), (unknown)	3
7	Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial 2023 ·Clinical Lymphoma Myeloma & Leukemia ·Matthew J. Matasar, Nancy L. Bartlett, Mazyar Shadman, Lihua E. Budde, Ian W. Flinn, Gareth P. Gregory, Won Seog Kim, Georg Heß, Dima El‐Sharkawi, Catherine Diefenbach, Huang Huang, Iris To, (unknown), (unknown), Antonia Kwan, Sarit Assouline	10
8	Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study breakdown → 2022 ·The Lancet Oncology ·Lihua E. Budde, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla, Miguel Canales, Sascha Dietrich, Keith Fay, Matthew Ku, Loretta J. Nastoupil, Chan Y. Cheah, Michael C. Wei, Shen Yin, Chi‐Chung Li, Huang Huang, Antonia Kwan, Elicia Penuel, Nancy L. Bartlett	244
9	TRAIL (Tolerability of R-CHOP in Aggressive non-Hodgkin Lymphoma): A Predictive Algorithm to Support Clinical Decision-Making 2020 ·Blood ·(unknown), Will Harris, Tarec Christoffer El‐Galaly, Antonia Kwan, Carsten Henneges, Joseph N. Paulson, Tina Nielsen	1
10	ONGOING PHASE 1B/2 TRIALS OF MOSUNETUZUMAB INVESTIGATING NOVEL TREATMENT REGIMENS FOR PATIENTS WITH B‐CELL NON‐HODGKIN LYMPHOMA (NHL) 2019 ·Hematological Oncology ·Lihua E. Budde, (unknown), Sunil Babu, Izidore S. Lossos, Juan Pablo Alderuccio, Julio C. Chávez, Herbert Eradat, Holly E. Holmes, Mehdi Hamadani, (unknown), Adam J. Olszewski, Erlene Seymour, Betsy Althaus, (unknown), (unknown), Antonia Kwan, Michael C. Wei, (unknown), Carol O’Hear, Javier Muñoz	1
11	Multisystem Anomalies in Severe Combined Immunodeficiency with Mutant BCL11B 2016 ·New England Journal of Medicine ·Divya Punwani, Yong Zhang, Jason Yu, Morton J. Cowan, (unknown), Antonia Kwan, Aashish N. Adhikari, Carlos O. Lizama, Bryce A. Mendelsohn, Shawn P. Fahl, (unknown), Rajgopal Srinivasan, Steven E. Brenner, David L. Wiest, Jennifer M. Puck	77
12	Successful newborn screening for SCID in the Navajo Nation 2015 ·Clinical Immunology ·Antonia Kwan, Diana Hu, (unknown), (unknown), (unknown), (unknown), Diana González‐Espinosa, Zhili Lin, Morton J. Cowan, Jennifer M. Puck	38
13	Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: Results of the first 2 years 2013 ·Journal of Allergy and Clinical Immunology ·Antonia Kwan, Joseph A. Church, Morton J. Cowan, Rajni Agarwal, Neena Kapoor, Donald B. Kohn, David B. Lewis, Sean McGhee, Theodore B. Moore, E. Richard Stiehm, Matthew H. Porteus, Constantino P. Aznar, Robert J. Currier, Fred Lorey, Jennifer M. Puck	143
14	Transcriptional Instability during Evolving Sepsis May Limit Biomarker Based Risk Stratification 2013 ·PLoS ONE ·Antonia Kwan, Michael Hubank, Asrar Rashid, Nigel Klein, Mark Peters	24
15	Newborn Screening for SCID Identifies Patients with Ataxia Telangiectasia 2012 ·Journal of Clinical Immunology ·(unknown), Antonia Kwan, Joseph A. Church, Diana González‐Espinosa, Fred Lorey, Ling Tang, Uma Sunderam, (unknown), Rajgopal Srinivasan, Steven E. Brenner, Jennifer M. Puck	60
16	Bim-mediated deletion of antigen-specific CD8+ T cells in patients unable to control HBV infection 2008 ·Journal of Clinical Investigation ·Andre Lopes, Paul Kellam, Abhishek Das, Claire Dunn, Antonia Kwan, (unknown), Dimitra Peppa, Richard Gilson, Adam J. Gehring, Antonio Bertoletti, Mala K. Maini	177
17	A prospective study of Kaposi's sarcoma-associated herpesvirus and Epstein–Barr virus in adults with human immunodeficiency virus-1 2006 ·British Journal of Cancer ·Robert Newton, L Carpenter, Delphine Casabonne, Valerie Beral, (unknown), Janet Darbyshire, I V Weller, Robin A. Weiss, Antonia Kwan, Dimitra Bourboulia, F Muñoz, Dimitris Lagos, Chris Boshoff	24
18	Autocrine Type I Interferon Amplifies Dendritic Cell Responses to Lipopolysaccharide via the Nuclear Factor‐κB/p38 Pathways 2006 ·Scandinavian Journal of Immunology ·Gabriele Pollara, (unknown), Antonia Kwan, Benny Chain, David R. Katz	12
19	Dendritic cells in viral pathogenesis: protective or defective? 2005 ·International Journal of Experimental Pathology ·Gabriele Pollara, Antonia Kwan, Philippa Newton, (unknown), Benny Chain, David R. Katz	54
20	Viral Bioinformatics: Computational Views of Host and Pathogen 2003 ·Novartis Foundation symposium ·Paul Kellam, (unknown), (unknown), Richard G. Jenner, Antonia Kwan	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact